Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review
Open Access
- 16 October 2020
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 8 (4), 1-5
- https://doi.org/10.14218/jcth.2020.00012
Abstract
Chronic liver disease (CLD) is an under-recognized epidemic that continues to increase in prevalence and is a major health concern. Silymarin, the active compound of Silybum marianum (Milk thistle), has historically been used in CLD. A significant barrier to silymarin use is its poor bioavailability. Attempts at improving the bioavailability of silymarin have led to a better understanding of formulation methods, pharmacokinetics, dosing, and associated drug interactions. Clinically, silymarin exerts its hepatoprotective effects through antioxidative, antifibrotic, anti-inflammatory, antitoxin, and anticancerous mechanisms of actions. Despite the use of silymarin being extensively studied in alcoholic liver disease, metabolic-associated fatty liver disease, viral hepatitis, and drug-induced liver injury, the overall efficacy of silymarin remains unclear and more research is warranted to better elucidate the role of silymarin in CLD, specifically regarding its anti-inflammatory effects. Here, we review the current biochemical and clinical evidence regarding silymarin in CLD.Keywords
This publication has 43 references indexed in Scilit:
- Silymarin in non alcoholic fatty liver diseaseWorld Journal of Hepatology, 2013
- Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon TherapyJAMA, 2012
- Differences in the Disposition of Silymarin between Patients with Nonalcoholic Fatty Liver Disease and Chronic Hepatitis CDrug Metabolism and Disposition, 2011
- Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in ratsJournal of Viral Hepatitis, 2008
- Global challenges in liver diseaseJournal of Hepatology, 2006
- Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performanceInternational Journal of Pharmaceutics, 2006
- Silymarin Protects Against Acute Ethanol‐Induced Hepatotoxicity in MiceAlcohol: Clinical and Experimental Research, 2006
- Natural Medicines Comprehensive DatabaseJournal of Consumer Health on the Internet, 2005
- Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibininJournal of Hepatology, 1996
- Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibininJournal of Hepatology, 1996